Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for non-ambulatory DMD patients with a confirmed mutation in the DMD gene on the 20th of ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT) , triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit ...

The Asian Investor sees significant improvement in XPeng’s (XPEV) vehicle margin profile, leading to a more positive outlook on the stock. In contrast, Seeking Alpha analysts have made notable ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.